time-to-symptom resolution
Fig 3 · Panel A
Panel A 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Matthew Tate, Christopher J R Illingworth, Gordon MacGregor, Laura Cunningham, Laura Divers, Elaine McCartney, Lucy Paterson, Caroline Kelly, Ann Shaw, Jonathan S Perkins, Vanessa Silva, Poppy Holland, Carol Dalton, Samantha Carmichael, Elizabeth Douglas, Pamela Surtees, Janet T Scott, Colin Berry, Sreenu Vattipally, Ana Da Silva Filipe, Lily Tong, Rory Gunson, GETAFIX trial co-investigators, Iain B McInnes, Robert Jones, Emma Thomson, Kevin G Blyth
Antimicrob Agents Chemother 69(8) e0005425
Early community treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection may reduce severe coronavirus disease (COVID-19) incidence. We evaluated clinical effectiveness, safety, and SARS-CoV-2 mutagenicity of favipiravir, an oral viral RNA polymerase inhibitor. We performed an open-label, community-based, randomized Phase III trial, recruiting non-hospitalized adults with mild COVID-19 (WHO ordinal severity score [OSS] ≤ 3). Positive cases were invited to web-based self-screening within 24 h using public health data. Exclusion criteria included symptoms for >7 days, pregnancy/breastfeeding, severe renal/liver disease, gout, and licensed antiviral eligibility. Participants were randomized 1:1 to 10 days favipiravir (Day 1: 3,600 mg; days 2-10: 1,600 mg) or no additional treatment. The primary endpoint was worst recorded OSS up to and including Day 15 (intention-to-treat). The target recruitment was 302. Secondary endpoints included adverse event (AE) rate to Day 60, time-to-viral clearance (TTVC), time-to-symptom resolution (TTSR), and SARS-CoV-2 sequencing variant rate (≥5% frequency) at Day 15 (registration ISRCTN: 31062548; EudraCT: 2020-001904-41). A total of 68,788 adults were invited, and 302 (0.4%) were subsequently randomized between December 2020 and July 2022 (favipiravir [n = 152]: standard care [n = 150]). Mean (SD) age was 47.2 (13.2), and 230/302 (76%) were vaccinated. Severe outcomes were infrequent, with no intensive care unit admissions/deaths. There was no difference in the primary endpoint: odds ratio 1.18 (95% confidence interval [CI] 0.63-2.20), TTSR (HR 1.03 [95% CI 0.81-1.31]), or TTVC (HR 1.13 [95% CI 0.65-1.97]). Favipiravir was well tolerated with few AEs but was associated with increased variant frequency, including C-to-U mutations. Community administration of favipiravir for mild COVID-19 was not associated with clinical benefits or safety concerns but was associated with SARS-CoV-2 mutagenicity.CLINICAL TRIALSThis study is registered with ISRCTN as 31062548 and with EU-CTR as 2020-001904-41.
1 个 Figure · 2 个 KM 面板
Fig 3 Kaplan-Meier plots summarizing (A) time-to-symptom resolution (TTSR) and (B) time-to-viral clearance (TTVC). A total of 266 out of 302 (88.1%) participants achieved symptom resolution (OSS ≤ 1) by Day 60; there was no difference in TTSR between favipiravir treated cases and controls. A total of 111 out of 302 (36.8%) cases had ≥1 follow-up PCR test and could be included in the TTVC analysis. There was no difference in TTVC between arms.
Fig 3 · Panel A
Panel A 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 3 · Panel B
Panel B 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。